IN2014CN00437A - - Google Patents

Info

Publication number
IN2014CN00437A
IN2014CN00437A IN437CHN2014A IN2014CN00437A IN 2014CN00437 A IN2014CN00437 A IN 2014CN00437A IN 437CHN2014 A IN437CHN2014 A IN 437CHN2014A IN 2014CN00437 A IN2014CN00437 A IN 2014CN00437A
Authority
IN
India
Prior art keywords
polypeptides
protein constructs
compositions
against ige
encode
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Meerts
Sigrid Cornelis
Guy Hermans
Jo Vercammen
Frank Kamiel Delphina Verdonck
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of IN2014CN00437A publication Critical patent/IN2014CN00437A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IN437CHN2014 2011-06-23 2012-06-25 IN2014CN00437A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161500449P 2011-06-23 2011-06-23
PCT/EP2012/062250 WO2012175740A1 (en) 2011-06-23 2012-06-25 Immunoglobulin single variable domains directed against ige

Publications (1)

Publication Number Publication Date
IN2014CN00437A true IN2014CN00437A (enExample) 2015-04-03

Family

ID=46458485

Family Applications (1)

Application Number Title Priority Date Filing Date
IN437CHN2014 IN2014CN00437A (enExample) 2011-06-23 2012-06-25

Country Status (6)

Country Link
EP (1) EP2723772A1 (enExample)
JP (1) JP2014525736A (enExample)
CN (1) CN104271598A (enExample)
AU (1) AU2012273928A1 (enExample)
IN (1) IN2014CN00437A (enExample)
WO (1) WO2012175740A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN105085677B (zh) * 2014-05-05 2019-01-18 中国科学院上海药物研究所 抗vegfr2人源纳米抗体ntv1及其制备方法和用途
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
CN109313183B (zh) * 2016-06-23 2022-10-21 埃博灵克斯股份有限公司 免疫球蛋白单可变结构域的改进的药代动力学测定
IL310340A (en) * 2016-12-07 2024-03-01 Ablynx Nv Improved serum albumin binding immunoglobulin single variable domains
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology PEPTIDE ALBUMIN BINDING CONJUGATES AND METHODS THEREOF
US20200392512A1 (en) * 2018-02-26 2020-12-17 Ablynx N.V. Nucleotide sequences encoding peptide linkers
CN108535493B (zh) * 2018-04-10 2020-11-03 北京康亿鸿科技发展有限公司 特异性过敏原IgE的检测方法
GB201818460D0 (en) * 2018-11-13 2018-12-26 Crescendo Biologics Ltd Single domain antibodies that bind human serum albumin
CN110716054A (zh) * 2019-09-11 2020-01-21 天津医科大学 一种血清亲细胞性免疫球蛋白e的定量检测试剂盒
CN111875706B (zh) * 2020-07-16 2021-03-30 广州康盛生物科技股份有限公司 一种抗人IgE蛋白的单域抗体及其应用
EP4547710A1 (en) * 2022-07-01 2025-05-07 ALK-Abelló A/S Displacers of ige-fceri
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
EP4665755A1 (en) 2023-02-17 2025-12-24 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
CN116640209B (zh) * 2023-04-06 2025-04-15 生物岛实验室 Rab11蛋白的特异性抗体及其制备方法与应用
CN116754773B (zh) * 2023-05-15 2024-06-07 江南大学 一种免疫球蛋白e的检测试剂盒
WO2025002295A1 (zh) * 2023-06-29 2025-01-02 苏州康宁杰瑞生物科技有限公司 免疫球蛋白Fc区结合蛋白

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB335768A (en) 1929-10-24 1930-10-02 Jacoviac Maurice Improvements in protecting devices for gramophone disc records
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
ATE348175T1 (de) 1992-07-17 2007-01-15 Dana Farber Cancer Inst Inc Method eder intrazellularen bindung von zielgerichteten molekülen
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
JPH08511160A (ja) 1993-06-09 1996-11-26 ユニリーバー・ナームローゼ・ベンノートシャープ 形質転換真カビによってＳｃＦｖフラグメントを含んでなる融合タンパク質を生産する方法
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
WO1998022141A2 (en) 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
AU3295299A (en) 1998-02-19 1999-09-06 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
ID30380A (id) 1999-04-22 2001-11-29 Unilever Nv Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal
ATE422545T1 (de) 1999-06-18 2009-02-15 Cv Therapeutics Inc Regulierung mittels atp binding cassette transporter proteins abc1
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
DK1233987T3 (da) 1999-11-29 2009-09-28 Bac Ip B V Immobiliserede enkelt-domæne antigenbindende molekyler
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
US20040053340A1 (en) 2000-12-13 2004-03-18 De Haard Johannes Joseph Protein arrays
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002355477B2 (en) 2001-08-03 2008-09-25 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
EP1517921B1 (en) 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
EP1565482B1 (en) 2002-10-23 2014-04-30 Ludwig Institute for Cancer Research Ltd. A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
WO2004041862A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
RU2357974C2 (ru) * 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2005293752A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
RU2464276C2 (ru) 2005-05-18 2012-10-20 Аблинкс Н.В. Улучшенные нанотела против фактора некроза опухоли-альфа
DK2444424T3 (en) 2005-05-20 2018-12-03 Ablynx Nv IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS
GB0520644D0 (en) * 2005-10-11 2005-11-16 Domantis Ltd Antibody polypeptide library screening and selected antibody polypeptides
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
EP2069402A2 (en) * 2006-09-08 2009-06-17 Ablynx N.V. Serum albumin binding proteins with long half-lives
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
US20080267949A1 (en) 2006-12-05 2008-10-30 Ablynx N.V. Peptides capable of binding to serum proteins
CA2678218A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
AU2008252853B2 (en) 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
US20110243954A1 (en) 2008-04-17 2011-10-06 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
JP2011516603A (ja) 2008-04-17 2011-05-26 アブリンクス エン．ヴェー． 血清タンパク質と結合することが可能なペプチド、並びにこれを含む化合物、構築物及びポリペプチド
ES2713864T3 (es) 2008-06-05 2019-05-24 Ablynx Nv Secuencias de aminoácidos dirigidas contra proteínas de la envuelta de un virus y polipéptidos que comprenden las mismas para el tratamiento de enfermedades virales
CA2788993A1 (en) 2010-02-05 2011-08-11 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same

Also Published As

Publication number Publication date
AU2012273928A1 (en) 2014-02-06
WO2012175740A1 (en) 2012-12-27
EP2723772A1 (en) 2014-04-30
JP2014525736A (ja) 2014-10-02
CN104271598A (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
IN2014CN00437A (enExample)
IN2014CN00414A (enExample)
TN2012000518A1 (en) Serum albumin binding molecules
CL2010001425A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
UA115546C2 (uk) Синтетичний транзитний пептид хлоропластів та спосіб його одержання
CL2013000566A1 (es) Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2014001055A1 (es) Proteina de union biespecifica que se enlaza al factor de necrosis tumoral (tnf) y la interleucina 17 (il-17); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso.
IN2014DN03451A (enExample)
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
CL2014001054A1 (es) Proteina de enlace que se une al factor de necrosis tumoral alfa (tnf-alfa); acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; su uso para tratar un trastorno asociado a tnf-alfa; y metodo para determinar la presencia de tnf-alfa en una muestra.
MX2013012844A (es) Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas.
EA201290567A1 (ru) Получение гетерологичных полипептидов в микроводорослях, внеклеточные микроводорослевые тельца, композиции и способы их получения и применения
IN2014DN05756A (enExample)
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
CL2013001625A1 (es) Proteina de union que se une especificamente a tnf-alfa; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar una enfermedad o trastorno asociado a tnf-alfa.
MY167125A (en) Modified proteins and peptides
CL2013000074A1 (es) Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2010001427A1 (es) Proteina de union que comprende una cadena polipeptidica capaz de unir un par de antigenos; acido nucleico aislado que codifica dicha proteina de union; vector y celula huesped; metodo para producir proteina de union; composicion farmaceutica que comprende dicha proteina.
EP2376647A4 (en) MONO LOADING SYSTEM FOR THE SELECTIVE INTRODUCTION OF NONNATIVE AMINO ACIDS IN PROTEINS ON THE BASIS OF AN IN VITRO PROTEIN SYNTHESIS SYSTEM
WO2012091564A3 (en) A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis
IN2014MN01562A (enExample)
MX355199B (es) Peptidos sinteticos de transito a cloroplastos derivados de brassica.
MX361434B (es) Proteínas de fusión npp1.
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
IN2013MN01394A (enExample)